Trials / Approved For Marketing
Approved For MarketingNCT02939820
Expanded Access Protocol of Patisiran for Patients With Hereditary ATTR Amyloidosis (hATTR)
Expanded Access Protocol of Patisiran for Patients With Hereditary Transthyretin-Mediated Amyloidosis (hATTR Amyloidosis) With Polyneuropathy
- Status
- Approved For Marketing
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Alnylam Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
The purpose of this study is to provide expanded access of patisiran to patients with hereditary transthyretin-mediated amyloidosis (hATTR).
Detailed description
Choosing to participate in an expanded access program is an important personal decision. Talk with your doctor and family members or friends about deciding to join a research study. To learn more about this study, please have your doctor contact the study research staff using the Contacts provided. For general information, see the links provided in More Information.
Conditions
- TTR-mediated Amyloidosis
- Amyloidosis, Hereditary
- Amyloid Neuropathies, Familial
- Familial Amyloid Polyneuropathies
- Amyloid Neuropathies
- Amyloidosis, Hereditary, Transthyretin-Related
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | patisiran (ALN-TTR02) | patisiran (ALN-TTR02) administered by intravenous (IV) infusion |
Timeline
- First posted
- 2016-10-20
- Last updated
- 2024-05-20
Source: ClinicalTrials.gov record NCT02939820. Inclusion in this directory is not an endorsement.